These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 38771516)

  • 1. Chelator boosted tumor-retention and pharmacokinetic properties: development of
    Zhang T; Ma X; Xu M; Cai J; Cai J; Cao Y; Zhang Z; Ji X; He J; Cabrera GOF; Wu X; Zhao W; Wu Z; Xie J; Li Z
    Eur J Nucl Med Mol Imaging; 2024 Sep; 51(11):3322-3333. PubMed ID: 38771516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of
    Fonseca Cabrera GO; Ma X; Lin W; Zhang T; Zhao W; Pan L; Li X; Barnhart TE; Aluicio-Sarduy E; Deng H; Wu X; Rakesh KP; Li Z; Engle JW; Wu Z
    J Nucl Med; 2024 Aug; 65(8):1250-1256. PubMed ID: 38871388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of neurotensin receptor 1 as potential biomarker for prostate cancer theranostic use.
    He T; Wang M; Wang H; Tan H; Tang Y; Smith E; Wu Z; Liao W; Hu S; Li Z
    Eur J Nucl Med Mol Imaging; 2019 Sep; 46(10):2199-2207. PubMed ID: 31264168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo evaluation of ⁶⁴Cu-radiolabeled KCCYSL peptides for targeting epidermal growth factor receptor-2 in breast carcinomas.
    Kumar SR; Gallazzi FA; Ferdani R; Anderson CJ; Quinn TP; Deutscher SL
    Cancer Biother Radiopharm; 2010 Dec; 25(6):693-703. PubMed ID: 21204764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems.
    Garrison JC; Rold TL; Sieckman GL; Figueroa SD; Volkert WA; Jurisson SS; Hoffman TJ
    J Nucl Med; 2007 Aug; 48(8):1327-37. PubMed ID: 17631556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes.
    Carlos Dos Santos J; Beijer B; Bauder-Wüst U; Schäfer M; Leotta K; Eder M; Benešová M; Kleist C; Giesel F; Kratochwil C; Kopka K; Haberkorn U; Mier W
    J Nucl Med; 2020 Jan; 61(1):70-79. PubMed ID: 31541034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aptamer imaging with Cu-64 labeled AS1411: preliminary assessment in lung cancer.
    Li J; Zheng H; Bates PJ; Malik T; Li XF; Trent JO; Ng CK
    Nucl Med Biol; 2014 Feb; 41(2):179-85. PubMed ID: 24373858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and Evaluation of 64Cu-DOTA-NT-Cy5.5 as a Dual-Modality PET/Fluorescence Probe to Image Neurotensin Receptor-Positive Tumor.
    Deng H; Wang H; Wang M; Li Z; Wu Z
    Mol Pharm; 2015 Aug; 12(8):3054-61. PubMed ID: 26162008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging Neurotensin Receptor in Prostate Cancer With
    Deng H; Wang H; Zhang H; Wang M; Giglio B; Ma X; Jiang G; Yuan H; Wu Z; Li Z
    Mol Imaging; 2017; 16():1536012117711369. PubMed ID: 28849698
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Wu W; Yu F; Zhang P; Bu T; Fu J; Ai S; You Q; Shi L; Shao G; Wang F; Hodolic M; Guo H
    J Nucl Med; 2022 Sep; 63(9):1394-1400. PubMed ID: 35177423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
    Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
    J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PET and SPECT imaging of a radiolabeled minigastrin analogue conjugated with DOTA, NOTA, and NODAGA and labeled with (64)Cu, (68)Ga, and (111)In.
    Roosenburg S; Laverman P; Joosten L; Cooper MS; Kolenc-Peitl PK; Foster JM; Hudson C; Leyton J; Burnet J; Oyen WJ; Blower PJ; Mather SJ; Boerman OC; Sosabowski JK
    Mol Pharm; 2014 Nov; 11(11):3930-7. PubMed ID: 24992368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical PET Imaging of NTSR-1-Positive Tumors with
    Li D; Minnix M; Allen R; Bading J; Chea J; Wong P; Bowles N; Poku E; Shively JE
    Cancer Biother Radiopharm; 2021 Oct; 36(8):651-661. PubMed ID: 32822229
    [No Abstract]   [Full Text] [Related]  

  • 14. Novel DOTA-neurotensin analogues for 111In scintigraphy and 68Ga PET imaging of neurotensin receptor-positive tumors.
    Alshoukr F; Prignon A; Brans L; Jallane A; Mendes S; Talbot JN; Tourwé D; Barbet J; Gruaz-Guyon A
    Bioconjug Chem; 2011 Jul; 22(7):1374-85. PubMed ID: 21662976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation and biological evaluation of (64)Cu labeled Tyr(3)-octreotate using a phosphonic acid-based cross-bridged macrocyclic chelator.
    Guo Y; Ferdani R; Anderson CJ
    Bioconjug Chem; 2012 Jul; 23(7):1470-7. PubMed ID: 22663248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference.
    Fani M; Del Pozzo L; Abiraj K; Mansi R; Tamma ML; Cescato R; Waser B; Weber WA; Reubi JC; Maecke HR
    J Nucl Med; 2011 Jul; 52(7):1110-8. PubMed ID: 21680701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Modular Dual-Labeling Scaffold That Retains Agonistic Properties for Somatostatin Receptor Targeting.
    Ghosh SC; Rodriguez M; Carmon KS; Voss J; Wilganowski NL; Schonbrunn A; Azhdarinia A
    J Nucl Med; 2017 Nov; 58(11):1858-1864. PubMed ID: 28572490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 64Cu-labeled 2-(diphenylphosphoryl)ethyldiphenylphosphonium cations as highly selective tumor imaging agents: effects of linkers and chelates on radiotracer biodistribution characteristics.
    Yang CT; Kim YS; Wang J; Wang L; Shi J; Li ZB; Chen X; Fan M; Li JJ; Liu S
    Bioconjug Chem; 2008 Oct; 19(10):2008-22. PubMed ID: 18763821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of 64Cu labeled GX1: a phage display peptide probe for PET imaging of tumor vasculature.
    Chen K; Sun X; Niu G; Ma Y; Yap LP; Hui X; Wu K; Fan D; Conti PS; Chen X
    Mol Imaging Biol; 2012 Feb; 14(1):96-105. PubMed ID: 21360213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of [
    Wang M; Zhang H; Wang H; Feng H; Deng H; Wu Z; Lu H; Li Z
    Mol Pharm; 2018 Aug; 15(8):3093-3100. PubMed ID: 29889537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.